Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BJSE:920433'
s Net Margin % Range Over the Past 10 Years
Min: -62.36 Med: 20.86 Max: 27.92
Current: -58.66
BJSE:920433's Net Margin % is ranked worse than 87.6% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.205
vs BJSE:920433: -58.66
Inner Mongolia Grand Pharmaceutical Co (BJSE:920433) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Inner Mongolia Grand Pharmaceutical Co Net Margin % Related Terms
Inner Mongolia Grand Pharmaceutical Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inner Mongolia Grand Pharmaceutical Co Net Margin % Chart
Inner Mongolia Grand Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Inner Mongolia Grand Pharmaceutical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inner Mongolia Grand Pharmaceutical Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Inner Mongolia Grand Pharmaceutical Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Inner Mongolia Grand Pharmaceutical Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inner Mongolia Grand Pharmaceutical Co (BJSE:920433) has a Net Margin % of -66.62% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Inner Mongolia Grand Pharmaceutical Co and its competitors. According to the industry distribution chart, Inner Mongolia Grand Pharmaceutical Co ranks #841 out of 960 companies in the Drug Manufacturers industry, placing it in the top 87.6%.
Is Inner Mongolia Grand Pharmaceutical Co's Net Margin % too high?
Inner Mongolia Grand Pharmaceutical Co's current Net Margin % is -66.62%. Based on the distribution chart, Inner Mongolia Grand Pharmaceutical Co ranks #841 out of 960 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Inner Mongolia Grand Pharmaceutical Co has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inner Mongolia Grand Pharmaceutical Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Inner Mongolia Grand Pharmaceutical Co ranks #841 out of 960 companies for Net Margin %. This places Inner Mongolia Grand Pharmaceutical Co in the lower half of its industry. The industry median Net Margin % is 5.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.21, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Inner Mongolia Grand Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inner Mongolia Grand Pharmaceutical Co's current Net Margin % is -66.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inner Mongolia Grand Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Inner Mongolia Grand Pharmaceutical Co (BJSE:920433) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥3.89, compared to a current price of ¥4.94 — trading 27% above its estimated fair value. The current Net Margin % is -66.62%. Inner Mongolia Grand Pharmaceutical Co's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Inner Mongolia Grand Pharmaceutical Co (BJSE:920433), the current Net Margin % is -66.62% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inner Mongolia Grand Pharmaceutical Co (BJSE:920433) Overvalued in 2026?
Based on GuruFocus' analysis, Inner Mongolia Grand Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥4.94 is trading 27% above its estimated GF Value™ of ¥3.89.
GuruFocus considers Inner Mongolia Grand Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for BJSE:920433:
Net Margin %: -66.62%
GF Value™: ¥3.89 vs. price of ¥4.94 (27% above fair value)
No single metric tells the full story. See the BJSE:920433 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inner Mongolia Grand Pharmaceutical Co Ltd is a pharmaceutical enterprise integrating the development of Mongolian medicine resources. It engages in the research and development, production, and sales of specialty medicines and general health products. The company's main business is the research and development, production of Chinese patent medicines (including ethnic medicines) and chemical preparations, and sales.
70GF Score
Get the complete analysis for BJSE:920433
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920433 has been successfully added to your 
